Ginkgo biloba extract individually inhibits JNK activation and induces c-jun degradation in human chondrocytes

Potential therapeutics for osteoarthritis

Ling Jun Ho, Li Feng Hung, Feng Cheng Liu, Tsung Yun Hou, Leou Chyr Lin, Chuan Yueh Huang, Jenn Haung Lai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Osteoarthritis (OA) is a common joint disorder with varying degrees of inflammation. The ideal anti-OA drug should have immunomodulatory effects while at the same time having limited or no toxicity. We examined the anti-inflammatory effects of Ginkgo biloba extract (EGb) in interleukin-1 (IL-1)-stimulated human chondrocytes. Chondrocytes were prepared from cartilage specimens taken from patients with osteoarthritis who had received total hip or total knee replacement. The concentrations of chemokines and the degree of cell migration were determined by ELISA and chemotaxis assays, respectively. The activation of inducible nitric oxide synthase (iNOS), mitogen-activated protein kinases (MAPKs), activator protein-1 (AP-1), and nuclear factor-kappaB (NF-κB) was determined by immunoblotting, immunohistochemistry, and electrophoretic mobility shift assay. We found that EGb inhibited IL-1-induced production of chemokines, which in turn resulted in attenuation of THP-1 cell migration toward EGb-treated cell culture medium. EGb also suppressed IL-1-stimulated iNOS expression and release of nitric oxide (NO). The EGb-mediated suppression of the iNOS-NO pathway correlated with the attenuation of activator protein-1 (AP-1) but not nuclear factor-kappaB (NF-κB) DNA-binding activity. Of the mitogen-activated protein kinases (MAPKs), EGb inhibited only c-Jun N-terminal kinase (JNK). Unexpectedly, EGb selectively caused degradation of c-Jun protein. Further investigation revealed that EGb-mediated c-Jun degradation was preceded by ubiquitination of c-Jun and could be prevented by the proteosome inhibitor MG-132. The results imply that EGb protects against chondrocyte degeneration by inhibiting JNK activation and inducing ubiquitination-dependent c-Jun degradation. Although additional research is needed, our results suggest that EGb is a potential therapeutic agent for the treatment of OA.

Original languageEnglish
Article numbere82033
JournalPLoS One
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 11 2013
Externally publishedYes

Fingerprint

Ginkgo biloba
chondrocytes
osteoarthritis
Nitric Oxide Synthase Type II
Chondrocytes
Interleukin-1
Osteoarthritis
phosphotransferases (kinases)
Phosphotransferases
Chemical activation
Transcription Factor AP-1
Mitogen-Activated Protein Kinases
Chemokines
Degradation
therapeutics
degradation
Assays
Nitric Oxide
extracts
Proto-Oncogene Proteins c-jun

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Ginkgo biloba extract individually inhibits JNK activation and induces c-jun degradation in human chondrocytes : Potential therapeutics for osteoarthritis. / Ho, Ling Jun; Hung, Li Feng; Liu, Feng Cheng; Hou, Tsung Yun; Lin, Leou Chyr; Huang, Chuan Yueh; Lai, Jenn Haung.

In: PLoS One, Vol. 8, No. 12, e82033, 11.12.2013.

Research output: Contribution to journalArticle

Ho, Ling Jun ; Hung, Li Feng ; Liu, Feng Cheng ; Hou, Tsung Yun ; Lin, Leou Chyr ; Huang, Chuan Yueh ; Lai, Jenn Haung. / Ginkgo biloba extract individually inhibits JNK activation and induces c-jun degradation in human chondrocytes : Potential therapeutics for osteoarthritis. In: PLoS One. 2013 ; Vol. 8, No. 12.
@article{0d36618538ef407680595bad9ab2ada6,
title = "Ginkgo biloba extract individually inhibits JNK activation and induces c-jun degradation in human chondrocytes: Potential therapeutics for osteoarthritis",
abstract = "Osteoarthritis (OA) is a common joint disorder with varying degrees of inflammation. The ideal anti-OA drug should have immunomodulatory effects while at the same time having limited or no toxicity. We examined the anti-inflammatory effects of Ginkgo biloba extract (EGb) in interleukin-1 (IL-1)-stimulated human chondrocytes. Chondrocytes were prepared from cartilage specimens taken from patients with osteoarthritis who had received total hip or total knee replacement. The concentrations of chemokines and the degree of cell migration were determined by ELISA and chemotaxis assays, respectively. The activation of inducible nitric oxide synthase (iNOS), mitogen-activated protein kinases (MAPKs), activator protein-1 (AP-1), and nuclear factor-kappaB (NF-κB) was determined by immunoblotting, immunohistochemistry, and electrophoretic mobility shift assay. We found that EGb inhibited IL-1-induced production of chemokines, which in turn resulted in attenuation of THP-1 cell migration toward EGb-treated cell culture medium. EGb also suppressed IL-1-stimulated iNOS expression and release of nitric oxide (NO). The EGb-mediated suppression of the iNOS-NO pathway correlated with the attenuation of activator protein-1 (AP-1) but not nuclear factor-kappaB (NF-κB) DNA-binding activity. Of the mitogen-activated protein kinases (MAPKs), EGb inhibited only c-Jun N-terminal kinase (JNK). Unexpectedly, EGb selectively caused degradation of c-Jun protein. Further investigation revealed that EGb-mediated c-Jun degradation was preceded by ubiquitination of c-Jun and could be prevented by the proteosome inhibitor MG-132. The results imply that EGb protects against chondrocyte degeneration by inhibiting JNK activation and inducing ubiquitination-dependent c-Jun degradation. Although additional research is needed, our results suggest that EGb is a potential therapeutic agent for the treatment of OA.",
author = "Ho, {Ling Jun} and Hung, {Li Feng} and Liu, {Feng Cheng} and Hou, {Tsung Yun} and Lin, {Leou Chyr} and Huang, {Chuan Yueh} and Lai, {Jenn Haung}",
year = "2013",
month = "12",
day = "11",
doi = "10.1371/journal.pone.0082033",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Ginkgo biloba extract individually inhibits JNK activation and induces c-jun degradation in human chondrocytes

T2 - Potential therapeutics for osteoarthritis

AU - Ho, Ling Jun

AU - Hung, Li Feng

AU - Liu, Feng Cheng

AU - Hou, Tsung Yun

AU - Lin, Leou Chyr

AU - Huang, Chuan Yueh

AU - Lai, Jenn Haung

PY - 2013/12/11

Y1 - 2013/12/11

N2 - Osteoarthritis (OA) is a common joint disorder with varying degrees of inflammation. The ideal anti-OA drug should have immunomodulatory effects while at the same time having limited or no toxicity. We examined the anti-inflammatory effects of Ginkgo biloba extract (EGb) in interleukin-1 (IL-1)-stimulated human chondrocytes. Chondrocytes were prepared from cartilage specimens taken from patients with osteoarthritis who had received total hip or total knee replacement. The concentrations of chemokines and the degree of cell migration were determined by ELISA and chemotaxis assays, respectively. The activation of inducible nitric oxide synthase (iNOS), mitogen-activated protein kinases (MAPKs), activator protein-1 (AP-1), and nuclear factor-kappaB (NF-κB) was determined by immunoblotting, immunohistochemistry, and electrophoretic mobility shift assay. We found that EGb inhibited IL-1-induced production of chemokines, which in turn resulted in attenuation of THP-1 cell migration toward EGb-treated cell culture medium. EGb also suppressed IL-1-stimulated iNOS expression and release of nitric oxide (NO). The EGb-mediated suppression of the iNOS-NO pathway correlated with the attenuation of activator protein-1 (AP-1) but not nuclear factor-kappaB (NF-κB) DNA-binding activity. Of the mitogen-activated protein kinases (MAPKs), EGb inhibited only c-Jun N-terminal kinase (JNK). Unexpectedly, EGb selectively caused degradation of c-Jun protein. Further investigation revealed that EGb-mediated c-Jun degradation was preceded by ubiquitination of c-Jun and could be prevented by the proteosome inhibitor MG-132. The results imply that EGb protects against chondrocyte degeneration by inhibiting JNK activation and inducing ubiquitination-dependent c-Jun degradation. Although additional research is needed, our results suggest that EGb is a potential therapeutic agent for the treatment of OA.

AB - Osteoarthritis (OA) is a common joint disorder with varying degrees of inflammation. The ideal anti-OA drug should have immunomodulatory effects while at the same time having limited or no toxicity. We examined the anti-inflammatory effects of Ginkgo biloba extract (EGb) in interleukin-1 (IL-1)-stimulated human chondrocytes. Chondrocytes were prepared from cartilage specimens taken from patients with osteoarthritis who had received total hip or total knee replacement. The concentrations of chemokines and the degree of cell migration were determined by ELISA and chemotaxis assays, respectively. The activation of inducible nitric oxide synthase (iNOS), mitogen-activated protein kinases (MAPKs), activator protein-1 (AP-1), and nuclear factor-kappaB (NF-κB) was determined by immunoblotting, immunohistochemistry, and electrophoretic mobility shift assay. We found that EGb inhibited IL-1-induced production of chemokines, which in turn resulted in attenuation of THP-1 cell migration toward EGb-treated cell culture medium. EGb also suppressed IL-1-stimulated iNOS expression and release of nitric oxide (NO). The EGb-mediated suppression of the iNOS-NO pathway correlated with the attenuation of activator protein-1 (AP-1) but not nuclear factor-kappaB (NF-κB) DNA-binding activity. Of the mitogen-activated protein kinases (MAPKs), EGb inhibited only c-Jun N-terminal kinase (JNK). Unexpectedly, EGb selectively caused degradation of c-Jun protein. Further investigation revealed that EGb-mediated c-Jun degradation was preceded by ubiquitination of c-Jun and could be prevented by the proteosome inhibitor MG-132. The results imply that EGb protects against chondrocyte degeneration by inhibiting JNK activation and inducing ubiquitination-dependent c-Jun degradation. Although additional research is needed, our results suggest that EGb is a potential therapeutic agent for the treatment of OA.

UR - http://www.scopus.com/inward/record.url?scp=84892420297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892420297&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0082033

DO - 10.1371/journal.pone.0082033

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e82033

ER -